Venetoclax with a hypomethylating agent or low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable [ID1564]

£656.3K GBP

Funder	National Institute for Health Research
Recipient Organization	University of Aberdeen
Country	United Kingdom
Start Date	Mar 19, 2021
End Date	Sep 14, 2021
Duration	179 days
Number of Grantees	1
Roles	Award Holder
Data Source	Europe PMC
Grant ID	`NIHR133147`

Grant Description

To appraise the clinical and cost effectiveness of venetoclax within its marketing authorisation for untreated acute myeloid leukaemia in people for whom intensive chemotherapy is not suitable.